Conclusion of recent 'osmolality trials' in preventing contrast-induced nephropathy by NAC--what is the standard?
Jo
Sang-Ho
SH
Koo
Bon-Kwon
BK
Youn
Tae-Jin
TJ
Kim
Hyo-Soo
HS
D000792:Angiography / Q000009:adverse effects / Q000379:methods*; D003287:Contrast Media / Q000009:adverse effects*; D055316:Cystatin C; D015891:Cystatins / Q000097:blood; D005919:Glomerular Filtration Rate / Q000502:physiology; D006801:Humans; D007472:Iohexol / Q000009:adverse effects; D007485:Ioxaglic Acid / Q000009:adverse effects; D007674:Kidney Diseases / Q000503:physiopathology / Q000517:prevention & control*; D009994:Osmolar Concentration; D016032:Randomized Controlled Trials as Topic; D014283:Triiodobenzoic Acids / Q000009:adverse effects
C525030:CST3 protein, human; D003287:Contrast Media; D055316:Cystatin C; D015891:Cystatins; D014283:Triiodobenzoic Acids; D007472:Iohexol; C044834:iodixanol; D007485:Ioxaglic Acid